Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Unknown 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 16Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

Pemetrexed 8Carboplatin 6Cisplatin 4Bevacizumab 4pembrolizumab 3anlotinib 3Platinum 2Paclitaxel 2tusamitamab ravtansine 1ixabepilone 1icotinib 1endostar protein 1camrelizumab 1Gefitinib 1Erlotinib Hydrochloride 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Non-squamous Non-small Cell Lung Cancer × anlotinib × Clear all
NCT03671538 2018-09-17

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

The First Affiliated Hospital of Nanchang University

Phase NA Unknown
62 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT03602027 2018-07-26

Phase I Study of the Combination of Anlotinib With Gefitinib

Second Affiliated Hospital of Nanchang University

Phase NA Unknown
9 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

NCT03566576 2018-06-25

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Fujian Cancer Hospital

Phase NA Unknown
18 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡